| Literature DB >> 31797974 |
Robin N Groen1, Marieke Wichers2, Johanna T W Wigman2, Catharina A Hartman2.
Abstract
A prominent hypothesis within the field of psychiatry is that the manifestation of psychopathology changes from non-specific to specific as illness severity increases. Using a transdiagnostic network approach, we investigated this hypothesis in four independent groups with increasing psychopathology severity. We investigated whether symptom domains became more interrelated and formed more clusters as illness severity increased, using empirical tests for two network characteristics: global network strength and modularity-based community detection. Four severity groups, ranging from subthreshold psychopathology to having received a diagnosis and treatment, were derived with a standardized diagnostic interview conducted at age 18.5 (n = 1933; TRAILS cohort). Symptom domains were assessed using the Adult Self Report (ASR). Pairwise comparisons of the symptom networks across groups showed no difference in global network strength between severity groups. Similar number and type of communities detected in the four groups exceeded the more minor differences across groups. Common clusters consisted of domains associated with attention deficit hyperactivity disorder (ADHD) and combined depression and anxiety domains. Based on the strength of symptom domain associations and symptom clustering using a network approach, we found no support for the hypothesis that the manifestation of psychopathology along the severity continuum changes from non-specific to specific.Entities:
Mesh:
Year: 2019 PMID: 31797974 PMCID: PMC6892855 DOI: 10.1038/s41598-019-54801-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic and clinical characteristics of the four severity groups based on CIDI.
| CIDI subthreshold (n = 492) | CIDI lifetime only (n = 205) | CIDI 12mo-no- treatment | CIDI 12mo-yes- treatment (n = 303) | df | Test statistics | p-value | |
|---|---|---|---|---|---|---|---|
| Female (%) | 47.9a | 53.9a,b | 60.1b | 60.2b | 3 | χ = 14.7 | 0.002 |
| Age (M ± SD) | 18.52a (0.61) | 18.51a (0.62) | 18.57a (0.60) | 18.58a (0.65) | 3 | F = 1.0 | 0.384 |
|
| |||||||
|
| 16.5a | 24.9a,b | 28.4b | 29.1b | 6 | χ = 23.3 | P < 0.001 |
|
| 53.0a | 49.2a | 49.8a | 51.9a | |||
|
| 30.5a | 25.9a,b | 21.8a,b | 19.0b | |||
|
| |||||||
|
| 68.5# | 53.7 | 57.0 | 58.4 | |||
|
| 0.8# | 4.4 | 6.9 | 15.8 | |||
|
| 28.5# | 28.8 | 15.8 | 13.5 | |||
|
| 25.4# | 31.2 | 22.3 | 40.9 | |||
|
| 18.3# | 4.9 | 16.2 | 15.2 | |||
| Comorbidity > 1 subthreshold or threshold diagnosis (%) | 44.1 | 27.8 | 35.0 | 46.5 | |||
| Adult Self Report total score (M ± SD) | 25.02 (16.97) | 34.90 (22.13) | 42.6 (24.60) | 51.9 (27.33) | 3 | F = 99.2 | P < 0.001 |
|
| 4.5a | 13.2b | 20.3b | 30.0c | 6 | χ = 155.6 | P < 0.001 |
|
| 6.5a | 12.7b | 12.4b | 20.1b | |||
|
| 89.0a | 74.1b | 67.4b | 49.8c | |||
|
| |||||||
|
| 0.59a (1.02) | 0.89 b (1.13) | 1.16b (1.34) | 1.61c (1.53) | 3 | F = 44.0 | P < 0.001 |
|
| 0.87a (1.22) | 1.44b (1.57) | 1.71b (1.78) | 2.34c (2.05) | 3 | F = 53.1 | P < 0.001 |
|
| 0.74a (1.04) | 1.00a (1.07) | 1.32b (1.23) | 1.68c (1.32) | 3 | F = 44.0 | P < 0.001 |
|
| 0.54a (0.77) | 0.78b (0.94) | 0.92b (0.94) | 1.22c (1.16) | 3 | F = 34.4 | P < 0.001 |
|
| 0.27a (0.79) | 0.39a (1.07) | 0.74b (1.43) | 1.10c (1.47) | 3 | F = 34.5 | P < 0.001 |
|
| 2.04a (1.70) | 2.69b (1.84) | 3.00b (1.91) | 3.73c (2.01) | 3 | F = 54.4 | P < 0.001 |
|
| 1.07a(1.19) | 1.49b(1.35) | 1.69b,c(1.48) | 1.96c(1.51) | 3 | F = 30.1 | P < 0.001 |
|
| 3.40a (2.18) | 3.88 a (2.21) | 4.77 b(2.54) | 5.40 c(2.59) | 3 | F = 50.7 | P < 0.001 |
|
| 1.15a (1.12) | 1.60b (1.40) | 1.90b,c (1.39) | 2.17c (1.55) | 3 | F = 41.8 | P < 0.001 |
|
| 0.83a (1.06) | 1.19b (1.29) | 1.39b (1.34) | 1.67c (1.37) | 3 | F = 31.2 | P < 0.001 |
|
| 0.55a (0.82) | 0.65a,b (0.88) | 0.83b (1.03) | 0.76b (1.0) | 3 | F = 6.5 | P = 0.001 |
|
| |||||||
| 0 | 41.7a | 50.6a | 45.0a | 46.4a | 6 | χ = 13.3 | P = 0.04 |
| 1 | 26.6a | 17.1b | 24.4a,b | 18.2b | |||
|
| 31.7a | 32.2a | 30.6a | 35.4a | |||
Each subscript letter denotes a subset of the severity groups whose column proportions do not differ significantly from each other at the p = 0.05 level.
1. Note: percentages reflect the proportion of individuals meeting criteria for at least one disorder from this category.
#Note: this reflects the % of individuals meeting subthreshold status for this diagnostic category.
Figure 1Network structure of symptom domains in four severity groups: (A) = CIDI subthreshold, (B) = CIDI lifetime only, (C) = CIDI 12mo-no-treatment, (D) = CIDI 12mo-yes-treatment. The network layout is kept constant (using average layout based on the four networks) to facilitate comparison. Symptom domains function as nodes; DEP indicates Core depressive symptoms; NCOG, Negative cognitions about oneself; FAT, Fatigue; FEAR, Fearfulness; PAIN, Medically unexplained pain; WOR, Worrying; IMP, Impulsivity; ATT, Attention problems; HYP, Hyperactivity/restlessness; EDYS, Emotion dysregulation; SUB, Substance use. Edges reflect the strength of pairwise symptom domain interrelations. To enable comparison of edge strength across networks, the strongest edge identified across all networks is set as maximum edge size. Thicker/darker edges imply stronger associations; green (solid) paths represent positive associations. Sub-communities identified by walktrap and edge-betweenness algorithms are indicated by different colors; domains with the same color belong to the same community.
Spearman correlations of network edge weights across severity groups.
| G1 | G2 | G3 | |
|---|---|---|---|
| G2 | 0.49 | ||
| G3 | 0.47 | 0.39 | |
| G4 | 0.67 | 0.33 | 0.53 |
Note: G1: CIDI subthreshold, G2: CIDI lifetime only, G3: CIDI 12mo-no-treatment, G4: CIDI 12mo-yes-treatment.
Permutation results global strength Network Comparison Test.
| G1G2 | G1G3 | G1G4 | G2G3 | G2G4 | G3G4 | |
|---|---|---|---|---|---|---|
| Global strength difference | 1.51 | 2.98 | 0.76 | 1.46 | 2.26 | 373 |
| P-value | 0.76 | 0.55 | 0.85 | 0.77 | 062 | 0.41 |
Note: G1: CIDI subthreshold, G2: CIDI lifetime only, G3: CIDI 12mo-no-treatment, G4: CIDI 12mo-yes-treatment.